News & Analysis as of August 4, 2025

Pharmaceutical Industry

+ Follow

The European Union is an economic and political partnership comprised of 27 nations within the Eurozone. The EU was established in 1948 to promote stability and cooperation among member states in the aftermath of WWII. The EU maintains a common currency as well as several intranational institutions, including the European Parliament and the European Commission. less -

Big Firms, Be Careful What You Say: First UK Competition Disparagement Decision Puts Large Companies On Notice

Mayer Brown on 6/20/2025

OVERVIEW - The UK Competition and Markets Authority (“CMA”) has recently published a decision accepting commitments from Vifor Pharma (“Vifor”). This brings to a close an unprecedented abuse of dominance investigation...more

Antitrust in focus - May 2025

A&O Shearman on 5/27/2025

This newsletter is a summary of the antitrust developments we think are most interesting to your business. Eliana Paredis (counsel based in Brussels) is our editor this month. She has selected: - European Commission kicks...more

Bulletin Concurrence XII - Paris │Avril ● Mai ● Juin ● Juillet ● Aout 2024

McDermott Will & Emery on 10/28/2024

1. CONTENTIEUX - NOUVEAU RISQUE DE REMISE EN CAUSE À POSTERIORI D’OPÉRATIONS NON NOTIFIABLES - Par une décision du 2 mai 2024, l’Autorité de la concurrence (ci-après l’ « Autorité ») a fait pour la première fois...more

European Antitrust Bimonthly Bulletin – July/August 2024

Wilson Sonsini Goodrich & Rosati on 9/6/2024

The "European Antitrust Bimonthly Bulletin” breaks down the major antitrust developments in Europe during the past two months into concise and actionable takeaways. ...more

The European Commission report on competition enforcement in the pharmaceutical sector

Hogan Lovells on 2/2/2024

On 26 January 2024, the European Commission published a report on competition enforcement in the pharmaceutical sector, highlighting the role of EU competition law in safeguarding market participants and consumers,...more

European Antitrust Bimonthly Bulletin – September/October 2023

Wilson Sonsini Goodrich & Rosati on 11/6/2023

The "European Antitrust Bimonthly Bulletin" breaks down the major antitrust developments in Europe during the past two months into concise and actionable takeaways....more

Antitrust in focus - July 2021

A&O Shearman on 8/2/2021

This newsletter is a summary of the antitrust developments we think are most interesting to your business. Please note that this is our final edition before we take a break over the summer, returning in September. Tjarda van...more

New Guidance on Article 22 EUMR Referrals to the European Commission

Latham & Watkins LLP on 4/1/2021

The European Commission (EC) has published new guidance on the application of the referral mechanism set out in Article 22 of the EU merger regulation (EUMR) allowing for mergers falling below national merger thresholds to be...more

2019 Highlights in Canadian Life Sciences IP and Regulatory Law

Smart & Biggar on 1/10/2020

In 2019, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. We review top developments below: 1) PMPRB: Amendments to Regulations will come into force July 1, 2020, court...more

Annual EU Competition Review 2018

McDermott Will & Emery on 2/19/2019

CARTELS & RESTRICTIVE AGREEMENTS - CJEU’S EYE-OPENING RULING ON ANTITRUST COMPLIANCE AND OFF-LABEL MISINFORMATION – C 179/16, HOFFMAN-LA ROCHE AND OTHERS V AGCM, 23 JANUARY 2018 – On 23 January 2018, the CJEU...more

European Commission Releases Pharmaceutical Anti-Competition Report

Goodwin on 2/6/2019

The European Commission has released a report summarizing the European Commission and the national competition authorities’ work to enforce European Union antitrust and merger rules in the pharmaceutical space. The report...more

EU General Court Dismisses Parallel Trade Group’s Dual-Pricing Complaint Against GSK

Skadden, Arps, Slate, Meagher & Flom LLP on 10/5/2018

On September 26, 2018, the EU General Court (the Court) upheld the European Commission’s refusal to reinvestigate GlaxoSmithKline SA’s (GSK) Spanish “dual-pricing” distribution arrangements, 20 years after the alleged conduct...more

Year in Review: Top 5 Foreign Market Developments in 2017

Goodwin on 12/27/2017

Here are our picks for the top-five most significant foreign market developments in the world of biosimilars in 2017...more

European Commission Sets its Sights on Allegedly Excessive Drug Prices

Jones Day on 6/20/2017

In the European Union, Big Pharma has been operating with a target on its back for the best part of the last decade. Following its 2008 sector inquiry into the pharmaceutical sector, the Commission vowed to clamp down on...more

Excessive pricing in pharmaceutical products attracts the European Commission's attention

Hogan Lovells on 5/23/2017

In recent years competition authorities in a number of EU Member States have stepped up in their pursuit against companies active in the Life Sciences sector for excessive pricing. Last week, the European Commission issued a...more

Global Inquiries into Drug Price Increases

Patterson Belknap Webb & Tyler LLP on 5/22/2017

European competition authorities announced this week an investigation into Aspen Pharmacare’s recent price hikes of five cancer drugs. The European Commission said in a press release that it had “information indicating that...more

January EU Competition Newsletter

BCLP on 1/25/2017

Digital and Pharma Merger Cases Raise Worry of Enforcement Gap in EU Merger Control - On 7 October 2016, the EU Commission launched a public consultation ("the Consultation") on the functioning of certain procedural and...more

17 Results

View per page

Page: of 1

European Union › Competition Authorities › Pharmaceutical Industry

"My best business intelligence, in one easy email…"